Clinical Trial

Vorinostat Dose-escalation After Allogeneic Hematopoietic Cell Transplantation

Active, Not Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
The objective of this study is to evaluate the maximum tolerated (MTD) of vorinostat used in combination with low-dose azacitidine after allogeneic hematopoietic cell transplantation (alloHCT) for prevention of relapse of childhood myeloid malignancies.
Protocol Amendment History 9 amendments
This ClinicalTrials.gov record has been amended 9 times since 2019-02-14; most recent amendment 2026-07-14.
Status change: Recruiting → Active, Not Recruiting 2025-08-06
Status change: Not Yet Recruiting → Recruiting 2019-07-09
Trial Details
NCT Number NCT03843528
Lead Sponsor Johns Hopkins All Children's Hospital
Conditions Acute Myeloid Leukemia, Myelodysplastic Syndromes, Mixed Phenotype Acute Leukemia, Juvenile Myelomonocytic Leukemia
Enrollment 15 participants
Start Date 2019-05-01
Primary Completion 2027-07-30 (estimated)
Study Completion 2027-10-30 (estimated)
Updated on ClinicalTrials.gov 2026-07-15